The U.K. National Health Service (NHS) has granted approval for what is thought to be the first use of electronic informed consent in England.
The U.K. National Health Service (NHS) has granted approval for what is thought to be the first use of electronic informed consent in England. The equipment for the trial will be provided by Mytrus, a California-based company.
The Health Research Authority (HRA), a division of the NHS, granted the approval to use e-Consent in a trial by a top-ten global pharmaceutical company, according to Mytrus. HRA, which oversees both research ethics committees and research innovation, was established to promote and protect the interests of patients participating in research. The plan is to use the results from the study to produce a paper that could serve as guidance for other national health authorities looking at ways to speed up the start of trials while assuring patients are at the center of decision-making.
Mytrus’ Enroll platform uses iPads to offer trial subjects an introductory overview and videos to reinforce key information. Potential trial subjects read the informed consent document, answer a set of questions to assess comprehension, and are prompted to review information they understand less well to help them make better, more informed decisions.
Research site staff can track patient metrics to determine where patients need counseling and dedicate time for each potential study participant to discuss the study with site staff before agreeing to give their consent. E-consent not only improves the patient experience, it also streamlines and speeds the costly enrollment process, according to the vendor.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.